What is the success rate of stem cell therapy for Spinal Muscular Atrophy?
No defensible stem-cell success rate exists for SMA. Stabilisation in an uncontrolled report cannot be separated from disease phenotype, age, supportive care or approved disease-modifying therapy. Review motor, respiratory, survival and adverse-event outcomes for the exact protocol.
What the evidence shows for Spinal Muscular Atrophy
The evidence and regulatory status of approved SMA medicines cannot be transferred to a stem-cell product. NINDS describes approved disease-modifying options including nusinersen and onasemnogene abeparvovec, alongside multidisciplinary respiratory, nutritional and rehabilitation care. See the NINDS SMA overview. Any cell proposal should identify its product, genetic rationale, protocol, age and disease-stage criteria, comparator and interaction with established treatment.
Am I a candidate? → · Spinal Muscular Atrophy: full overview → · Spinal Muscular Atrophy cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.